Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 10/20 | 0.64 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8245425 | 0.85 | NR4A2 (0.48) | NR4A2KMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL9572754 | 0.83 | KCNH2 (0.59) | NR4A2BRD4KMT2ALMNAMEN1 | |
| SCHEMBL8355113 | 0.83 | KMT2A (0.63) | NR4A2KMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL29263733 | 0.82 | NR4A2 (0.64) | NR4A2BRD4KMT2ALMNAMEN1 | |
| SCHEMBL13415459 | 0.82 | NR4A2 (0.64) | NR4A2BRD4KMT2AKDM4E | |
| SCHEMBL7985067 | 0.82 | NR4A2 (0.64) | NR4A2ALDH1A1 | |
| SCHEMBL19202547 | 0.82 | NR4A2 (0.64) | NR4A2BRD4KMT2ALMNAMEN1 | |
| SCHEMBL13114466 | 0.81 | KDM4E (0.64) | NR4A2KMT2ALMNAMEN1ALDH1A1 | |
| SCHEMBL13415462 | 0.81 | ALDH1A1 (0.49) | NR4A2KMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL6590142 | 0.81 | MAPT (0.51) | NR4A2KMT2ALMNAALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061759-B1 | CYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2013-03-27 | — | — | EP | disclosed |
| US-8324251-B2 | Cyclic modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324251-B2 | Cyclic modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100093798-A1 | CYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-15 | — | — | US | disclosed |
| US-20100093798-A1 | CYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-15 | — | — | US | disclosed |
| WO-2008042926-A1 | CYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-10 | — | — | WO | disclosed |
| US-5877202-A | Indole derivatives useful to treat estrogen-related neoplasms and disorders | AVENTISUB II INC. | 1999-03-02 | — | — | US | disclosed |
| EP-0746544-B1 | NOVEL INDOLE DERIVATIVES USEFUL TO TREAT ESTROGEN-RELATED NEOPLASMS AND DISORDERS | MERRELL PHARMA INC (US) | 1998-09-09 | — | — | EP | disclosed |
| CN-1141627-A | Indole derivatives for the treatment of estrogen-related tumors and diseases | MERRELL DOW PHARMA (US) | 1997-01-29 | — | — | CN | disclosed |
| EP-0746544-A1 | NOVEL INDOLE DERIVATIVES USEFUL TO TREAT ESTROGEN-RELATED NEOPLASMS AND DISORDERS | MERRELL PHARMACEUTICALS INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| WO-1995022524-A1 | NOVEL INDOLE DERIVATIVES USEFUL TO TREAT ESTROGEN-RELATED NEOPLASMS AND DISORDERS | MERRELL PHARMACEUTICALS INC. (US) | 1995-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093798-A1 | CYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CXCR1, CCR3 | NR4A2 561/4885ABL1 4269/4885BRD4 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.